TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Improvement in Ishak fibrosis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Undetectable serum HBV DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MPA area under the curve at Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral morphine maximum plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) of oral morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine glucuronide/morphine ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safe driving performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of T2DM
Endpoint domain: Mortality/survival
Primary endpoint: Evaluative responses about major depressive disorder
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in Non-Suicidal Self-Injury (NSSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Children's Global Assessment Scale (C-GAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness against pig tungiasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time lost to injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foveal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in HBV DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in hepatic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in fibrosis degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hot flushes and leg cramps
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiac and cerebrovascular events
Endpoint domain: Adverse events/effects
Primary endpoint: Failure to initiate antihypertensive therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiovascular disease endpoints
Endpoint domain: Mortality/survival
Primary endpoint: FM score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ARAT score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of outpatient appointments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in MRI parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pore size improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin lightness index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mindfulness facet of Observe
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: levels of spatter bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of atrial and brain natriuretic peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Retention of knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Isometric lumbar muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Dynamic lifting capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: newly diagnosed stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Genital tract concentrations of TFV gel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose reductions due to adverse events
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: cognitive development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quality-adjusted life years (QALE)
Endpoint domain: Mortality/survival
Primary endpoint: Life expectancy (LE)
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidences of diabetes-related complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: reduction in waist circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increase in HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary oxalate excretion (UOx x V)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary calcium excretion (Uca x V)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CaOx crystallization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean central corneal thickness (CCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AC inflammation reaction grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal and urinary adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Musculoskeletal and connective tissue disorders
Endpoint domain: Adverse events/effects
Primary endpoint: Eradication of axial reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Patient-centered communication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Communication proficiencies
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Occurrence of high-grade cervical intraepithelial neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Implant failure
Endpoint domain: Mortality/survival
Primary endpoint: serum troponin T levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: wound healing process
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: migration of fibroblasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extent of wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International normalized ratio (INR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: Aspartate aminotransferase (AST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: Alanine aminotransferase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: 3-year metastasis-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Pain level during FNAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total ARPQ score change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of subjects with no alcohol-related problem
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic Respiratory Questionnaire dyspnea domain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 6-minute-walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentrations of inflammatory markers (CRP, TNF-α, IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite of death of any cause, myocardial infarction, or cerebrovascular accident
Endpoint domain: Mortality/survival
Primary endpoint: Time to first analgesic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total acetaminophen consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: gag reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of mother-to-child HBV transmission
Endpoint domain: Mortality/survival
Primary endpoint: 90-day modified Rankin Scale 0-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in IL-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in IL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in IL-4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in IL-10 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Loss of medial and lateral tibial cartilage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement of symptoms from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amnesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of major or minor vascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rates of acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mild genital symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: increase in stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in urge to smoke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total lean body mass (LBM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in DeltaL*
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Deltab*
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ascending colon emptying t1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improved bowel function scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Oral Assessment Guide scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma lipoprotein‐associated phospholipase A2 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plaque lipoprotein‐associated phospholipase A2 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC24 for glimepiride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC24 for metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum concentration for metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: craving response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCO area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCO severity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chest-tube output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of elastin fiber preparations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted mean change in the SARA total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean cost per assessment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: overall percentage of lesions correctly assessed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subclinical TBI progression rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 24-h intragastric pH values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of time intragastric pH was above 3, 4, 5 or 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum adiponectin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Problems with sexual function
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of tooth agenesis excluding third molars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Prevalence of third molar agenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: recurrent encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: time until achievement of discharge criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of back pain
Endpoint domain: Adverse events/effects
Primary endpoint: morphine consumption at day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morphine consumption at day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perception of pain after mammogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Illicit opioid use in the 30 days before the 6-month interview
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of buprenorphine OAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rate of H. pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma free fatty acid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Beta-hydroxybutyrate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MACCE (Major Adverse Cardiac and Cerebrovascular Events)
Endpoint domain: Mortality/survival
Primary endpoint: Bleeding rate
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum plasma concentration (Cmax) of doravirine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC0-24 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough plasma concentration (C24 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to BF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSADT following testosterone recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distant failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: endoscopic recurrence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Formation of hematomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: C. trachomatis eradication rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of clinical success (cure plus improvement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reconstruction failure
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the pRPE/BM shape measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of optic disc swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTV coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OAR sparing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose conformity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change from baseline in GmTSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean AUC of change from baseline in HAQ-DI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Use of cardiovascular drugs after one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients receiving lifestyle intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inquiries about patient compliance to medical treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total amount of morphine during postoperative first 24 hrs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triple-positive cultures
Endpoint domain: Adverse events/effects
Primary endpoint: Positive cultures from the joint
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in mean Numerical Rating Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine equivalents used
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Brachial-ankle pulse wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QT(c) interval change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum serum concentrations of etonogestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: maximum serum concentrations of ethinylestradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: absolute bioavailability for etonogestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: absolute bioavailability for ethinylestradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of puncture of the opposite cortex during operation
Endpoint domain: Adverse events/effects
Primary endpoint: reduced use of any bottles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: calories from milk bottles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total calories
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total symptom score of knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough reflex sensitivity (log C (2))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cough reflex sensitivity (log C (5))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Median reduction of focal seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 50% responder rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall quality of care for older patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Identification of fetuses at risk for adverse neonatal outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of care option focused on comfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of neck lymphnode
Endpoint domain: Mortality/survival
Primary endpoint: Functions of chewing, swallowing and speaking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteoradionecrosis occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: fewer incontinence episodes weekly
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower daily urinary frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: higher proportion had no incontinence episodes at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ventricular tachycardia episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Score of dyspareunia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Bond strength to dentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height Velocity (HV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IGF-I SDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed Overall Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CA19-9 decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotection (HAI ≥1:40)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of renal dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Postoperative serum creatinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: TMFL (Total Menstrual Fluid Loss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PBAC (Pictorial Blood Assessment Chart) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes